Spatial architecture contributes to failure of bulk biomarker-guided neoadjuvant immunotherapy selection in bladder cancer: The DUTRENEO study

Enrique Grande, Mustafa Sibai, Daniela Grases, Elena Andrada, Oscar Reig, Marc Escobosa, Ainara Azueta, Daniel Castellano, Javier Puente, Jaime Martínez de Villarreal, Albert Font, Teresa Alonso-Gordoa, Raquel Benítez, Ane Moreno-Oya, Mario Álvarez-Maestro, Javier Burgos, M. Angel Climent, Mario Domínguez, Patricia Galván, Isabel Galante, Juan F. García, Elena Perez, Xavier García del Muro, Félix Guerrero-Ramos, Miriam Marqués, Pablo Maroto, Jesús M. Paramio, Alvaro Pinto, Aleix Prat, Núria Malats, Ignacio Durán, Eduard Porta-Pardo, Francisco X. Real · 2026

Read Spatial architecture contributes to failure of bulk biomarker-guided neoadjuvant immunotherapy selection in bladder cancer: The DUTRENEO study by Enrique Grande, Mustafa Sibai, Daniela Grases, Elena Andrada, Oscar Reig, Marc Escobosa, Ainara Azueta, Daniel Castellano, Javier Puente, Jaime Martínez de Villarreal, Albert Font, Teresa Alonso-Gordoa, Raquel Benítez, Ane Moreno-Oya, Mario Álvarez-Maestro, Javier Burgos, M. Angel Climent, Mario Domínguez, Patricia Galván, Isabel Galante, Juan F. García, Elena Perez, Xavier García del Muro, Félix Guerrero-Ramos, Miriam Marqués, Pablo Maroto, Jesús M. Paramio, Alvaro Pinto, Aleix Prat, Núria Malats, Ignacio Durán, Eduard Porta-Pardo, Francisco X. Real (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13400163.txt.

Description

Enrique Grande and colleagues report DUTRENEO, a randomized phase 2 trial testing whether an 18-gene tumor inflammation signature could select bladder cancer patients for immunotherapy before surgery, in this 2026 study. It could not. Patients were stratified by the bulk-tissue score and randomized around neoadjuvant checkpoint inhibitor treatment. The trial missed its primary endpoint, showing the bulk score does not enrich for responders when used in real time.

Rather than stopping at the negative result, the team asked why, profiling tumors with single-cell spatial transcriptomics: 377 genes measured across roughly 5.4 million cells. Response turned out to depend on geography that bulk assays average away: how close CD8 T cells sit to cancer cells, and whether checkpoint molecules are co-expressed inside cancer-rich neighborhoods. In non-responders, fibroblast-rich communities walled the immune cells out. The study is a cautionary landmark for biomarker-guided trial design.

Catalog record

CREATOREnrique Grande, Mustafa Sibai, Daniela Grases, Elena Andrada, Oscar Reig, Marc Escobosa, Ainara Azueta, Daniel Castellano, Javier Puente, Jaime Martínez de Villarreal, Albert Font, Teresa Alonso-Gordoa, Raquel Benítez, Ane Moreno-Oya, Mario Álvarez-Maestro, Javier Burgos, M. Angel Climent, Mario Domínguez, Patricia Galván, Isabel Galante, Juan F. García, Elena Perez, Xavier García del Muro, Félix Guerrero-Ramos, Miriam Marqués, Pablo Maroto, Jesús M. Paramio, Alvaro Pinto, Aleix Prat, Núria Malats, Ignacio Durán, Eduard Porta-Pardo, Francisco X. Real
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE107249
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13400163

Browse the full library · About the Tower of Babel